Last mentioned: Mar 26, 2026
Market Outperformance
Grail shares surge as market sentiment shifts from bearish to bullish, leading the biotech sector gains.
TD Cowen Upgrade
Analysts upgrade GRAL, calling the recent selloff a 'buying opportunity' and stabilizing the stock price.
Leadership & Trial Volatility
CEO Bob Ragusa announces retirement; reports surface regarding a setback in the NHS-Galleri clinical trial.
After a volatile start to March marked by a CEO transition and clinical trial setbacks, Grail (GRAL) shares staged a massive recovery this week. The rebound was fueled by a high-profile analyst upgrade and a market correction following what many saw as an overreaction to recent headwinds.
The FDA has proposed a groundbreaking regulatory system designed to streamline the approval of customized, 'N-of-1' therapies for ultra-rare diseases. This shift marks a transition from traditional mass-market drug evaluation to a platform-based approach, potentially unlocking significant venture investment in precision medicine.
Amai Proteins has received FDA GRAS approval for its designer protein sweetener, Sweelin, marking a pivotal regulatory milestone for the precision fermentation industry. This clearance allows the Israeli food-tech startup to begin large-scale commercialization in the U.S. food and beverage market.
This page surfaces every story mentioning FDA across our startup coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running startup beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where FDA was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |